Amarin Co. plc (NASDAQ:AMRN) Short Interest Update

Amarin Co. plc (NASDAQ:AMRN) was the recipient of a large decrease in short interest in April. As of April 15th, there was short interest totalling 15,840,000 shares, a decrease of 12.1% from the March 31st total of 18,020,000 shares. Based on an average trading volume of 1,680,000 shares, the short-interest ratio is currently 9.4 days.

Institutional Investors Weigh In On Amarin

A number of large investors have recently bought and sold shares of AMRN. Raymond James Financial Services Advisors Inc. grew its position in Amarin by 35.7% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 649,152 shares of the biopharmaceutical company’s stock worth $597,000 after acquiring an additional 170,670 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Amarin by 16.8% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 122,498 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 17,613 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. boosted its position in Amarin by 18.9% in the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 129,200 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 20,500 shares during the last quarter. LCM Capital Management Inc boosted its position in Amarin by 103.4% in the 3rd quarter. LCM Capital Management Inc now owns 704,159 shares of the biopharmaceutical company’s stock valued at $648,000 after buying an additional 358,000 shares during the last quarter. Finally, Hayek Kallen Investment Management boosted its position in Amarin by 83.6% in the 3rd quarter. Hayek Kallen Investment Management now owns 622,643 shares of the biopharmaceutical company’s stock valued at $573,000 after buying an additional 283,564 shares during the last quarter. 22.25% of the stock is currently owned by institutional investors.

Amarin Price Performance

Shares of AMRN traded up $0.01 during mid-day trading on Friday, reaching $0.87. The company had a trading volume of 490,768 shares, compared to its average volume of 1,207,184. Amarin has a twelve month low of $0.65 and a twelve month high of $1.49. The company’s 50-day moving average is $0.97 and its 200-day moving average is $0.93. The company has a market capitalization of $359.30 million, a P/E ratio of -6.25 and a beta of 1.98.

Amarin (NASDAQ:AMRN) last released its quarterly earnings results on Thursday, February 29th. The biopharmaceutical company reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.04. The business had revenue of $74.71 million for the quarter, compared to analyst estimates of $72.46 million. Amarin had a negative return on equity of 10.47% and a negative net margin of 19.26%. As a group, equities analysts expect that Amarin will post -0.14 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Amarin in a report on Friday, January 12th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the stock. According to MarketBeat, Amarin currently has an average rating of “Hold” and a consensus target price of $1.08.

About Amarin

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.